Reuters |
EU approves Sanofi and Regeneron's dupilumab in eczema
Reuters Atopic dermatitis is a chronic type of skin inflammation also known as eczema, which in severe cases causes constant, and often unbearable, itching. A human monoclonal antibody, Dupixent is designed to specifically inhibit two key proteins which are … Sanofi's Dupixent gets Europe eczema nod Sanofi, Regeneron claim EU approval for eczema drug Dupixent Regeneron and Sanofi Announce Approval of DUPIXENT® (dupilumab) to Treat Adult Patients with Moderate-to … |
Tag Archives: Regeneron’s
AbbVie’s positive eczema study drags down Regeneron’s shares – Reuters
Reuters |
AbbVie's positive eczema study drags down Regeneron's shares
Reuters AbbVie Inc said on Thursday its experimental drug to treat adults with moderate-to-severe eczema met the main goal in a mid-stage study, dragging down … AbbVie Inc (ABBV) Stock Surges on Positive Eczema Study AbbVie shares rally on positive eczema study, competitor Regeneron drops How AbbVie Could Chip Away At Regeneron's Potential Blockbuster |